Clinical trial for treating anxiety in animals with cannabis gets approval

Canopy Growth Corporation and Canopy Health Innovations will research the effectiveness of using CBD to treat anxiety in animals

Bruce Linton, Founder and CEO for Canopy Growth Corporation. Peter J Thompson

Canopy Growth Corporation and its wholly-owned subsidiary Canopy Health Innovations Inc. have been approved to research the effectiveness of cannabidiol (CBD) to treat anxiety in animals. The company recently announced the approval from the Veterinary Drug Directorate of Health Canada.

A clinical trial will be conducted by Canopy Animal Health, a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals.


The approval comes in the form of a No Objection Letter for the use of a proprietary CBD enriched oil formulation, previously administered in preclinical dosing and safety studies, as a potential therapy for anxiety. The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ont.

“Our passion to create safe and effective products for animals is driven by the love we share for our pets,” said Marc Wayne, managing director of Canopy Health, in a news release.

The trial approvals mark a significant milestone in making cannabis-based drugs accepted and recommended by veterinarians, said Wayne.

Canopy Animal Health continues to build a strong portfolio of safety and dosing data for certain animals which it plans to share with the veterinary community and pet owners, through publications and scientific conferences. The company also recently announced that it acquired the remaining unowned interest in Canopy Health, a move that will further accelerate efforts to research effective cannabis formulations and dose delivery systems for human and animals.


« »